Does Humana Cover Actos (Pioglitazone)?

Humana Formulary Placement for Pioglitazone

Generic pioglitazone sits on Tier 1 or Tier 2 of most Humana formularies, making it one of the least expensive branded diabetes medications available through the insurer. That placement applies across Humana's commercial HMO, PPO, and the majority of its Medicare Advantage (MA) plans.

Brand-name Actos occupies a different position. Takeda's branded product carries a list price near $60 per month, but since pioglitazone lost patent exclusivity in 2012, Humana has progressively moved the brand to non-preferred or non-formulary status. If your plan does list brand Actos, expect Tier 3 cost-sharing, often $35 to $75 per fill. The generic version, by contrast, averages $10 to $20 at retail pharmacies and frequently falls under $0 copay on Humana plans with strong generic benefits.

To confirm your specific plan's tier placement, search "pioglitazone" on Humana's online formulary tool or call the member services number on the back of your ID card. Formulary documents are updated quarterly, so a mid-year check is worth the effort. The FDA-approved prescribing information for pioglitazone confirms its indication as an adjunct to diet and exercise for glycemic control in type 2 diabetes, which is the basis for formulary inclusion [1].

Prior Authorization Requirements on Humana Plans

Most Humana plans do not require prior authorization (PA) for generic pioglitazone prescribed for type 2 diabetes. The drug's long track record and low cost make it a straightforward formulary item that pharmacies can dispense without additional insurer review.

Exceptions exist in three scenarios. First, if a prescriber writes for brand-name Actos instead of the generic, Humana may require a PA demonstrating medical necessity for the brand (such as a documented allergy to a generic filler ingredient). Second, off-label prescribing for nonalcoholic steatohepatitis (NASH) or metabolic-associated steatotic liver disease (MASLD) often triggers a coverage review. Third, certain Humana Medicare Advantage plans with narrow formularies may impose quantity limits or require documentation that the patient has tried and failed metformin.

When a PA is required, expect Humana to request the following documentation from the prescribing clinician: a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.x), current HbA1c value, a list of previously tried antidiabetic agents, and a rationale for selecting pioglitazone over formulary alternatives. Turnaround for standard PA decisions is typically 72 hours for commercial plans and 24 hours for Medicare Advantage urgent requests, per CMS Medicare Managed Care Manual guidelines [2].

Step Therapy: Does Humana Require Metformin First?

Some Humana plans enforce step therapy protocols that require a trial of metformin before covering pioglitazone. This is common in both commercial group plans and select Medicare Advantage products.

The clinical rationale is straightforward. The American Diabetes Association (ADA) Standards of Care recommend metformin as first-line pharmacotherapy for type 2 diabetes in patients without contraindications [3]. Pioglitazone, a thiazolidinedione (TZD), is positioned as a second-line or add-on agent. Humana's step therapy requirement mirrors this guideline hierarchy.

To satisfy the step therapy requirement, the prescriber typically needs to document one of the following: a 90-day trial of metformin at maximally tolerated dose with inadequate glycemic control (HbA1c remaining above target), a documented contraindication to metformin (eGFR <30 mL/min, history of lactic acidosis), or intolerance manifested by persistent gastrointestinal side effects despite dose titration.

If you have already tried metformin through a different insurer or provider, ask your physician to include that treatment history in the step therapy override request. Humana does accept external documentation of prior metformin use.

Off-Label Use for NASH: Coverage Barriers

Pioglitazone has strong clinical evidence supporting its use in nonalcoholic steatohepatitis. The PIVENS trial (N=247), published in the New England Journal of Medicine in 2010, demonstrated that pioglitazone 30 mg daily significantly improved hepatic steatosis, lobular inflammation, and insulin resistance compared to placebo over 96 weeks in patients with biopsy-confirmed NASH without diabetes [4]. The resolution-of-NASH rate was 47% with pioglitazone versus 21% with placebo.

Despite this evidence, Humana coverage for pioglitazone prescribed specifically for NASH is inconsistent. Commercial plans may approve it with sufficient documentation, but Medicare Advantage plans face a structural barrier: pioglitazone's FDA-approved indication is limited to type 2 diabetes, and CMS coverage determinations generally do not extend to off-label uses unless supported by specific CMS-recognized compendia.

The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends pioglitazone for biopsy-proven NASH, noting that "pioglitazone can be used to treat steatohepatitis in patients with and without type 2 diabetes mellitus" [5]. Prescribers can reference this guideline in appeal documentation, though success rates on MA plans remain lower than on commercial products.

A practical workaround: if the patient has both type 2 diabetes and NASH, the prescriber can list the diabetes diagnosis as the primary indication. The drug's NASH benefit is then an expected secondary therapeutic effect, not the billed indication.

What Pioglitazone Costs on Humana

The out-of-pocket cost for pioglitazone through Humana varies by plan type, pharmacy network, and deductible status. Here is what to expect across common scenarios.

On Humana commercial plans with Tier 1 placement, generic pioglitazone typically costs $0 to $10 per 30-day supply. Many Humana employer-sponsored plans waive copays entirely for Tier 1 generics. On Medicare Advantage plans, copays during the Initial Coverage Phase generally range from $1 to $15. During the Coverage Gap (formerly the "donut hole"), the Inflation Reduction Act provisions cap insulin costs at $35 per month, and while pioglitazone is not insulin, generic Tier 1 drugs in the gap still carry relatively low cost-sharing, often $5 to $15.

For members who reach the Catastrophic Coverage Phase, cost-sharing drops to $0 for most Part D drugs under the 2025 IRA $2,000 annual out-of-pocket cap, which remains in effect for 2026. This cap makes pioglitazone essentially free for high-utilization Medicare beneficiaries once the threshold is reached.

Cash-pay pricing without insurance averages $10 to $20 per month for generic pioglitazone 15 mg, 30 mg, or 45 mg tablets through major retail and mail-order pharmacies. GoodRx and similar discount platforms occasionally bring the price below $8. Given these low cash prices, some patients find it simpler to pay out of pocket rather than manage PA or step therapy requirements.

How to Appeal a Humana Denial for Pioglitazone

If Humana denies coverage for pioglitazone, you have structured appeal rights that differ between commercial and Medicare Advantage plans.

For Humana commercial plans, the process follows a two-level internal appeal. File the first-level appeal within 180 days of the denial. Include the prescriber's letter of medical necessity, relevant lab results (HbA1c, liver function tests if NASH is involved), documentation of prior drug trials, and applicable guideline references. Humana must respond within 30 days for non-urgent appeals. If the first-level appeal is denied, a second-level appeal goes to an independent physician reviewer within Humana.

Medicare Advantage appeals follow CMS-mandated timelines. The first level is a plan reconsideration, decided within 7 days (72 hours for expedited requests). If denied, the case automatically advances to an Independent Review Entity (IRE). For Humana MA plans, this is MAXIMUS Federal Services, which conducts an independent medical review. The MAXIMUS review must be completed within 7 days of receipt.

Beyond MAXIMUS, MA beneficiaries can escalate to an Administrative Law Judge (ALJ) hearing if the amount in controversy meets the annual threshold ($185 for 2026), then to the Medicare Appeals Council, and finally to federal district court. Few pioglitazone denials reach ALJ level because of the drug's low cost, but the pathway exists.

Key appeal tips: reference the ADA Standards of Care and, for NASH cases, the AASLD practice guidance. Include specific HbA1c values, dates of prior medication trials, and a clear statement of why pioglitazone is medically necessary over formulary alternatives.

Pioglitazone vs. Formulary Alternatives on Humana

Humana formularies include several oral antidiabetic agents that compete with pioglitazone for second-line or add-on use. Understanding their relative positioning can help if you face a denial.

Metformin (Tier 1) is the universal first-line agent and the step therapy prerequisite. Sulfonylureas like glipizide and glimepiride (Tier 1) are inexpensive but carry hypoglycemia risk that pioglitazone avoids. SGLT2 inhibitors (empagliflozin, dapagliflozin) sit on Tier 2 or Tier 3 and cost significantly more, but they carry cardiovascular and renal outcome benefits demonstrated in trials like EMPA-REG OUTCOME (N=7,020), which showed a 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo [6].

Pioglitazone offers distinct advantages that justify its use when formulary position is questioned. It does not cause hypoglycemia. It improves insulin sensitivity at the adipocyte and hepatic level. The PROactive trial (N=5,238) showed a 16% reduction in the composite of all-cause mortality, nonfatal MI, and stroke in pioglitazone-treated patients with type 2 diabetes and macrovascular disease, though the primary composite endpoint did not reach significance (P=0.095 for the primary; P=0.027 for the main secondary endpoint) [7].

For prescribers building a case for pioglitazone specifically, emphasize the patient's NASH comorbidity, insulin resistance phenotype, or intolerance to alternative agents.

Using Manufacturer Savings Programs with Humana

Brand-name Actos no longer carries an active manufacturer copay card from Takeda, as the drug has been available generically since 2012. Patients searching for "Actos savings card" will find expired or discontinued programs.

For generic pioglitazone, manufacturer-sponsored savings programs are not applicable because generic drugs are produced by multiple companies without branded copay assistance. The most effective cost-reduction strategies for Humana members using pioglitazone are: (1) confirm generic substitution at the pharmacy, (2) use Humana's preferred mail-order pharmacy for 90-day fills at reduced copays, (3) apply a GoodRx or RxSaver discount if the cash price is lower than the insurance copay, and (4) for Medicare beneficiaries, check eligibility for the Low-Income Subsidy (Extra Help) program through Social Security Administration, which can reduce Part D copays to $0 to $4.50 per generic fill.

Humana also participates in the CenterWell Pharmacy (formerly Humana Pharmacy) mail-order system, which often provides the lowest per-unit cost for Tier 1 generics. A 90-day supply of pioglitazone through CenterWell may cost less than a single retail fill.

Safety Considerations That Affect Coverage Decisions

Humana's coverage policies for pioglitazone reflect the drug's known safety profile, which includes specific black-box and labeled warnings that prescribers must address in PA documentation.

The FDA black-box warning for pioglitazone concerns congestive heart failure (CHF). Thiazolidinediones cause dose-related fluid retention that can exacerbate or precipitate CHF, and pioglitazone is contraindicated in NYHA Class III or IV heart failure [1]. Humana may flag prescriptions for patients with concurrent CHF diagnosis codes (ICD-10 I50.x) and request clinical justification.

Bladder cancer risk has been a longstanding concern. A 10-year observational study published in the BMJ (N=145,806) found a modestly elevated risk of bladder cancer with pioglitazone use exceeding 24 months (HR 1.63, 95% CI 1.22 to 2.19) [8]. The FDA reviewed this data and maintained pioglitazone's market status but updated the label to include bladder cancer as a warning. Some Humana plans include bladder cancer screening questions in their PA criteria for long-term pioglitazone use.

Weight gain is another consideration. Pioglitazone causes a mean weight gain of 2 to 4 kg over 12 months, driven by fluid retention and subcutaneous adipose expansion. This is relevant because Humana will not cover pioglitazone for weight loss. The drug causes weight gain, not loss, and any claim requesting coverage for a weight-related indication will be denied.

Bone fracture risk is elevated in women taking pioglitazone. The PROactive trial observed increased fracture rates in female participants (5.1% vs. 2.5% placebo) [7]. Prescribers should document bone density considerations, especially in postmenopausal women, when submitting PA requests.

The recommended starting dose is 15 mg or 30 mg once daily, titrated to a maximum of 45 mg daily based on glycemic response and tolerability, per the FDA prescribing information [1].